Company intelligence / Profile preview

LumiThera

Poulsbo, Washington, United Stateslumithera.com ↗

Ownership: Private
Development stage: Other

Overview

Valeda Light Delivery System demonstrated statistically significant improvement in best corrected visual acuity (>5 letters over baseline at two years) in dry AMD patients. The pivotal LIGHTSITE III trial met its primary endpoint with a strong safety profile. FDA authorization was granted November 2024 as the first approved treatment to improve vision in dry AMD.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically photobiomodulation devices using LED and laser light)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Nikon Corporation

Beyond the preview

Go deeper on LumiThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LumiThera.

Explore the full profile